Unexpected drug residuals in human milk in Ankara, capital of Turkey

Ayşe Meltem Ergen and Siddika Songül Yalçın

Abstract

Background: Breast milk is a natural and unique nutrient for optimum growth and development of the newborn. The aim of this study was to investigate the presence of unpredictable drug residues in mothers’ milk and the relationship between drug residues and maternal-infant characteristics.

Methods: In a descriptive study, breastfed infants under 3 months of age and their mothers who applied for child health monitoring were enrolled for the study. Information forms were completed for maternal-infant characteristics, breastfeeding problems, crying and sleep characteristics of infants. Maternal and infant anthropometric measurements and maternal milk sample were taken. Edinburgh Postpartum Depression Scale was applied to mothers. RANDOX Infiniplex kit for milk was used for residual analysis.

Results: Overall, 90 volunteer mothers and their breastfed infants were taken into the study and the mean age of the mothers and their infants was 31.5 ± 4.2 years and 57.8 ± 18.1 days, respectively. Anti-inflammatory drug residues in breast milk were detected in 30.0% of mothers and all had tolfenamic acid. Overall, 94.4% had quinolone, 93.3% beta-lactam, 31.1% aminoglycoside and 13.3% polymycin residues. Drugs used during pregnancy or lactation period were not affected by the presence of residues. Edinburgh postpartum depression scores of mothers and crying and sleeping problems of infants were similar in cases with and without drug residues in breast milk. When controlling confounding factors, maternal body mass index alterations were detected to be significantly lower in mothers with anti-inflammatory drug residues in breast milk than in their counterparts (p = 0.017).

Conclusions: Our study suggests that there are unpredictable drug residues in the milk of many mothers. Anti-inflammatory drug exposure might affect maternal weight change during the postpartum period. Further studies are required to evaluate the impact of drug residues on maternal and infant health.

Keywords: Breast milk, Drug remnants, Crying, Sleep, Growth, Postnatal maternal weight

Background

Various pharmaceuticals are given to livestock, fish farms, and beekeeping in order to treat infections, ensure efficiency and growth of products [1]. However, metabolites of veterinary medicinal products given in inappropriate time, dosage and indications, can persist in animals’ muscle, organs and products, and then contaminate people who consume these animals’ products [2]. Remarkably, many drugs’ residuals were reported in food products derived from animal husbandry in different parts of the world [1, 3–9]. The residuals pose a risk of developing some adverse effects including hypersensitivity reaction, antimicrobial resistance, disruption of normal intestinal flora, bone marrow depression and carcinogenicity [10–12]. Therefore, food safety is now universally recognised as a public health priority [13]. These public health concerns are extremely important for mother-foetus pairs during the gestational and lactational periods. Screening all the nutrients consumed by mothers is impossible. However, breast milk can be used for evaluation of the mother-infant environment. Given the possibility of transfer to infants via milk, pharmaceuticals including antibiotics and nonsteroidal anti-inflammatory drugs (NSAID) are carefully prescribed by doctors to mothers during lactation with prescription of doctors [14–16]. Similarly, we predicted that a
There are many studies on the effects of drug residue exposure to human health [19, 20]. There is no study in the literature about the impact of drug residues on maternal anthropometric change after delivery, postpartum depression (PPD) and infant crying and sleeping characteristics. The prevalence of PPD varies from country to country and its incidence varies from 0 to 60% [21]. The prevalence of PPD ranged from 21.2 to 25.0% in Turkey [22]. PPD adversely affects infant mental health [23, 24]. Potential risk factors of PPD include low self-esteem, low social support, low socioeconomic status, stressful life, poor marital relationship, unplanned pregnancy, complications during pregnancy, and prenatal depression [25–27]. However, the pathogenesis of PPD is not fully known [28]. On the other hand, the heptachlor epoxide levels in breast milk samples were found to be positively correlated with Postpartum Bonding Questionnaire, Mother-to-Infant Bonding Scale and indexes of Brief Symptom Inventory indicating some maternal psychopathologies and bonding problems while causing no change in PPD [29]. It is not yet known whether maternal environmental pollutants including pharmaceuticals have an impact on the occurrence of PPD.

Sleeping and crying problems among infants were common in the first 3 months postpartum, but the cause could not be elucidated [30]. Maternal drug use can be considered to lead to breast problems and premature discontinuation of breastfeeding and to change the sleeping and crying patterns of infants [10]. Therefore, it can be hypothesised that exposure to veterinarian drugs could affect maternal psychopathologies, breastfeeding success and the well-being of infants.

The primary purpose of the study was to investigate the presence in breast milk of any residues of drugs that the mother did not take. At the same time it was aimed to investigate the effect of drug residues in breast milk on PPD, breastfeeding success and sleep and crying characteristic of infants.

**Methods**

This descriptive study was done in mother-infant pairs who applied for child health follow-up in Hacettepe University İhsan Doğramaci Children’s Hospital between August 2017 and March 2018. Mothers who were breastfeeding their infants and agreed to participate to the study were included. Twin babies and non-breastfed babies were not taken into the study. Any mothers who had taken antibiotics or NSAID for the last 10 days were not included into the study.

This study protocol was examined by Hacettepe University Medical Faculty Non-Interventional Clinical Research Ethics Committee and was approved on August 24, 2017 with the report numbered GO 17/687. Mothers who participated in the study signed voluntary consent form.

**Study protocols**

The investigator filled in the mother-infant information form by using a 10-min face-to-face interview technique. The information form contains maternal characteristics [maternal age, education, occupation, history of disease and drug usage (vitamin, antibiotic, anti-parasite, NSAID, vb) during pregnancy and lactation, weight at delivery, smoke exposure] and infant characteristics (age, gender, gestational length, birth type, birth weight, neonatal jaundice presence of concomitant disease, sleep and crying problems according to mothers, feeding type). Edinburgh Postpartum Depression Scale (EPDS) was applied to mothers on admission. Both maternal (weight and height) and infant anthropometric measures (weight, length and head circumference) were taken on admission. After breastfeeding for 5 min, approximately 5 mL of human milk were taken into polypropylene tubes by a hand milking method. The collected samples were stored at −20 °C until analysis.

**Study variables**

The history of the baby’s crying was determined by how many hours the baby was crying in the day, whether there was excessive crying or if they had a colic-style crying. “Inconsolable crying” was defined as the mother’s perception of infant crying as excessive and colic-style crying was defined as restlessness, agitation, and crying for at least 2 weeks, 3 days per week, more than 3 h per day and unexplained by another reason.

The body mass index (BMI) of mothers was calculated from values at time of delivery and admission. Anthro program was used to determine “z scores of length, weight and head circumference (respectively, HAZ, WAZ and HCZ respectively) for age and sex” of infants [31].

EPDS was developed by Cox in 1987 [32]. The validity and reliability study of EPDS was conducted by Engindeniz in 1996, in Turkey [33]. The scale consists of 10 items and the items are evaluated as 4-point Likert and scored between 0 and 3. The lowest score is 0 and the highest score is 30. In the evaluation of item 3, 5, 6, 7, 8, 9 and 10, the scoring is reversed.
InfiniPlex biochip kit for milk [Cat no: Ref EV4076, Lot no 9034 (13233EV), RANDOX food diagnostics, London, United Kingdom] was used for residue analysis in milk samples according to manufacturer’s instructions [34]. InfiniPlex test menu is 98% compliant with EU regulated antibiotics and reports 44 assays with 132 contaminants (Additional file 1: Table S1).

**Statistical analysis**

Statistical analyses were performed with SPSS 23.0 package program (SPSS Inc., Chicago, IL). Descriptive statistics of cases were given as mean, standard deviation, and distribution rates were given as n, %.

To examine the effect of residues on mother-infant characteristics, the sample was divided into two groups according to the presence of the drug residues in cases having detection rates between 10 and 90%. These drugs are NSAID, aminoglycosides and polymyxin. Chi-square analysis was used to compare independent group ratios. The suitability of the case parameters to normal distribution was examined by Kolmogorov Smirnow test. Differences in mother-infant characteristics were analysed by Student-t test or Mann-Whitney U test according to distribution pattern.

The impact of both the presence of breast milk residue (NSAID, polymyxin AND aminoglycoside) and maternal drug usage (NSAID and antibiotic) during the early postpartum period on the mother’s BMI changes after birth was analysed with general linear models adjusted for maternal age, smoke exposure, gestational length, birth type, maternal BMI at birth, maternal chronic disease, breastfeeding type, infant age.

After controlling for maternal age, maternal chronic disease, smoke exposure, gestational length, birth type, infant’s WAZ score at birth and infant age, general linear models were used to detect both the effect of breast milk residues and maternal self-reported drug use on the infant’s WAZ score on admission in only exclusive breast fed infants.

*P* values below 0.05 were considered statistically significant.

**Results**

The study was performed on 90 mothers who were still breastfeeding their babies between 18 and 93 days postpartum.

**General characteristics of mothers**

Maternal age, education, working status, smoking status and disease status were given in Table 1. The age range of the mothers was between 24 and 44 years with a mean age of 31.5 years. More than half of the mothers (58.9%) stated no smoking or environmental exposure. Overall, 34.4% of the mothers reported acute or chronic disease; 15 mothers had hypothyroidism, two allergic asthma, two ankylosing spondylitis, and three heart failure. Hypertension was found in 5.6% of mothers, high blood glucose level in 10.1% and urinary tract infection in 13.3% in pregnancy follow-up. 32.2% of the mothers had a disease that required medication. 26.7% of mothers said that they used antibiotics during pregnancy, 32.2% used NSAID and 4.4% steroids. There was a history of use of antibiotics in 42.2% and NSAID in 53.3% of mothers from delivery to the end of the first week. On admission, there was no case taking antibiotics or NSAID within the last 10 days.

Overall, 34.4% of mothers stated some breastfeeding problems; cracked nipple (21.1%), insufficient milk (20.0%), breast engorgement (6.7%), breast refusal (7.8%), mastitis (3.3%).

The mean EPDS score of the mothers was 7.3 ± 5.3 points. While 25.6% of the mothers had an EPDS score of 10 points or more, 16.7% had 13 points or more.

**General characteristics of babies**

The mean age was 57.8 ± 18.1 days, 38 (42.2%) babies were male and 46.7% were the first child of the family (Table 1). The mean birth weight of the babies was 3161 ± 471 g. Overall, 18 babies (20%) were found to have a disease; eight infants had cardiac pathology (atrial septal defect, ventricular septal defect, patent ductus arteriosus and tetralogy of fallot), and one had hypothyroidism, one had spinal muscular atrophy and one had epilepsy. It was reported that 37.8% of infants had jaundice during the first week of life; however, indirect hyperbilirubinemia levels had been below 12 g/dl. The ratio of exclusively breastfed infants was 80%. Of all, 63 mothers said that their babies were sleeping regularly. The rate of babies crying for 2 h or more per day was 14.4%, and there were only 7 (7.8%) infants who had untimely crying according to the mother’s declaration.

**Drug residues in breast milk samples**

No drug residues were detected in only four mothers’ milk.

Some residues of NSAID were found in 30.0% of the mother’s milk (Table 2). All of these cases had tolfenamic acid residues, but in one case 5-OH flunixin, chloramadinone, metamizol and meloxicam residues were detected at the same time.

Residues of quinolone and beta-lactams (94.4 and 93.3%, respectively) were detected in most of the mothers’ milk (Table 2).

Residues of aminoglycosides were revealed in 28 (31.1%) mothers’ milk samples. Of them 27 had spectinomycin,
one had gentamicin. Polymyxin residue was found in 12 (13.3%) breast milk samples.

Three breast milk samples contained lincomycin. Two breast milk samples contained sulphonamide residues; one having dapsone and another having both sulphonamide and sulphamethazine residues. There were two breastmilk samples containing amphenicoll residues. One breastmilk sample contained novobiocin. Macrolide residue, tyloclin, was revealed in only one mother’s milk. Only one breastmilk sample contained both baquiloprim and trimetoprim in diminopyridine group drug residue. Nitroxinil residue, an antiparasitic drug, were detected in three breastmilk samples.

Table 1 General characteristics of mother-infant pairs, n = 90

| Maternal characteristics                                  | Infant characteristics                      |
|-----------------------------------------------------------|--------------------------------------------|
| Age, yrs                                                  | Gestational duration, weeks                |
| 31.5 ± 4.2                                                | 38.2 ± 1.4                                 |
| Education level, > 12 yrs                                  | Birth type, caesarean delivery             |
| 63 (70.0)                                                 | 62 (68.9)                                  |
| Occupation, Working                                       | Birth order, first child                   |
| 26 (28.9)                                                 | 42 (46.7)                                  |
| Smoking exposure during lactational period                | Infants’ age, days,                        |
| No smoking                                                | 57.8 ± 18.1                                |
| 53 (58.9)                                                 | Gender, Male                               |
| Second-hand smoking                                       | 38 (42.2)                                  |
| 28 (31.1)                                                 | Intensive care requirement after birth     |
| Self smoking                                              | 19 (21.1)                                  |
| 9 (10.0)                                                  | Jaundice at the first week, presence       |
| Any maternal health problem                               | 34 (37.8)                                  |
| 31 (34.4)                                                 | Infant health problem                      |
| Drug usage during gestational period                      |                                            |
| Vitamin/mineral usage                                     |                                            |
| 75 (83.3)                                                 |                                            |
| Antiinflamatuar usage                                     |                                            |
| 29 (32.2)                                                 |                                            |
| Antibiotic usage                                          |                                            |
| 24 (26.7)                                                 |                                            |
| Any drug usage                                            |                                            |
| 86 (95.6)                                                 |                                            |
| Drug usage during lactational period                      |                                            |
| Vitamin/mineral usage                                     |                                            |
| 39 (43.3)                                                 |                                            |
| Antiinflamatuar usagea                                    |                                            |
| 48 (53.3)                                                 |                                            |
| Antibiotic usagea                                         |                                            |
| 38 (42.2)                                                 |                                            |
| Any drug usage                                            |                                            |
| 75 (83.3)                                                 |                                            |
| Edinburg postpartum depression score                      |                                            |
| 7.3 ± 5.3                                                 |                                            |
| Anthropometric values                                     |                                            |
| Weight gain during pregnancy, kg                         |                                            |
| 15.2 ± 5.4                                                |                                            |
| Weight at delivery, kg                                    |                                            |
| 73.9 ± 11.6                                               |                                            |
| Height on admission, cm                                    |                                            |
| 163.3 ± 5.7                                               |                                            |
| BMI (kg/m²) at delivery                                   |                                            |
| 27.8 ± 4.5                                                |                                            |
| BMI (kg/m²) on admission                                  |                                            |
| 26.2 ± 4.2                                                |                                            |
| BMI change from birth to admission                        |                                            |
| −1.56 ± 3.20                                              |                                            |
| Values were mean ± SD or n (%)                            |                                            |
| aonly for the first 5–10 days after delivery. On admission, mothers had stated the intake of neither antibiotics nor NSAID for the last 10 days |

Maternal-infant characteristics according to the status of NSAID in breastmilk

More than half of mothers had reported the intake of NSAID within the first 5 days after delivery. However, maternal age, educational status, occupation, history of drug use and cigarette contact did not affect the presence of NSAID residue (Table 3). High scores for the EPDS frequency did not differ according to the contact of NSAID. The age, gender, birth type, birth order and gestational length did not differ according to the contact with NSAID.

While the frequency of neonatal jaundice in the first weeks postpartum was 51.9% in infants with NSAID residues in breast milk, it was 31.7% in the no residue detected group (p = 0.071). Detection of NSAID residues slightly increased breastfeeding problems (p = 0.073). The crying and sleep characteristics of the infants were not influenced by the presence of NSAID residue in milk (Table 3).

Maternal-infant characteristics according to the presence of antibiotic residues in breast milk

Nearly half of mothers had reported the intake of antibiotics after delivery within the first 5 days. However, no
mother had stated the use of quinolone, aminoglycoside or polymyxin for the previous 1 year. Detection rates of aminoglycoside and polymyxin antibiotic residues were between 10 and 90% and further evaluation was done.

Maternal age, educational status, working status, history of any drug use during lactation, smoke exposure and EPDS \( \geq 13 \) were similar in groups with or without containing aminoglycoside antibiotic residues in breast milk (Table 4). Similarly, the presence or absence of polymyxin drug residue in breast milk did not differ according to maternal and infant baseline characteristics. Neither the detection of aminoglycoside nor polymyxin drug residues in breast milk affect the need for intensive care for the baby, the history of jaundice, breastfeeding problems, sleep and crying problems (Table 4).

Veterinary drug residuals and anthropometric evaluations of mother-infant pairs
The BMI of the mother at delivery and on admission did not differ according to the presence of the residues of NSAID, aminoglycoside and polymyxin in her milk (Table 3). However, in multivariate analysis, compared to counterparts, maternal BMI change from birth to delivery was observed significantly lower both in cases with NSAID residuals \((-0.51 \pm 0.53, -2.07 \pm\)

| Table 2 Detection rates of drug residues in mother’s milk according to their groups and nomenclature |
|---------------------------------------------------------------|
| Residue drug groups                        | n (%) | Positive residue drugs | n (%) | Residues, not found in breast milk |
|---------------------------------------------------------------|
| Antiinflammatory                                            | 27 (30.0) | 5-OH Flunixin | 2 (2.2) | Phenylbutazone |
| Antiinflammatory                                            |         | Chlormadinone | 1 (1.1) |                  |
| Antiinflammatory                                            |         | Metamizole | 1 (1.1) |                  |
| Antiinflammatory                                            |         | Tolfenamic acid | 27 (30.0) |                  |
| Antiinflammatory                                            |         | Meloxicam | 1 (1.1) |                  |
| Diaminopirimidine                                           | 1 (1.1) | Baquioloprim | 1 (1.1) |                  |
| Diaminopirimidine                                           |         | Trimethoprim | 1 (1.1) |                  |
| Aminoglycoside                                              | 28 (31.1) | Spectinomycin | 27 (30.0) | Tobramycin |
| Aminoglycoside                                              |         | Streptomycin | 1 (1.1) | Apramycin |
| Aminoglycoside                                              |         | Neomisin | 1 (1.1) | Hygromycin B |
| Aminoglycoside                                              |         | Gentamicin | 1 (1.1) | Kanamycin |
| Quinolone                                                   | 85 (94.4) | Quinolone | 85 (94.4) |                  |
| Lincosamide                                                 | 3 (3.3) | Lincomycin | 3 (3.3) | Pirlimycin |
| Sulphonamidine                                               | 2 (2.2) | Sulphonamides | 1 (1.1) | Sulphapyridine, |
| Sulphonamidine                                               |         | Sulphamethazine | 1 (1.1) | Sulphaguanidine |
| Macrolide                                                   | 1 (1.1) | Tylosin | 1 (1.1) | Erythromycin, Spiramycin |
| Penicillin                                                  | 84 (93.3) | Beta-Lactams | 84 (93.3) |                  |
| Corticosteroid                                               | 3 (3.3) | Methylprednisolone | 3 (3.3) | Dexamethasone |
| Amphenicol                                                  | 2 (2.2) | Amphenicol | 2 (2.2) |                  |
| Aminocoumarin                                               | 1 (1.1) | Novobiocin | 1 (1.1) |                  |
| Antiparasitic                                                | 3 (3.3) | Nitrooxylin | 3 (3.3) |                  |
| Polymyxin                                                   | 12 (13.3) | Polymyxin | 12 (13.3) |                  |
| Naphthalene ringed ansamycins                               | 0 (0.0) |                  |       | Rifaximin |
| Streptogramins                                               | 0 (0.0) |                  |       | Virginiamycin |
| Growth Promoter                                              | 0 (0.0) |                  |       | Ractopamine |
| Polypeptide                                                  | 0 (0.0) |                  |       | Bacitracin |
| Tetracycline                                                 | 0 (0.0) |                  |       | Tetracycline |
| Cefalosporin                                                 | 0 (0.0) |                  |       | Cefalexin, Cefuroxime |

**Beta-lactams assay** includes “penicillin compounds (ampicillin, amoxicillin, cloxacillin, dicloxacillin, penicillin G, penicillin V and nafcillin) and cephalosporin compounds (cefacetitil, cefapiurin, cefalonium, cefazolin, cefoperazone, cefquinome and ceftiofur)” with detection limit of 0.35–25.00 ppb

**Quinolones assay** includes “ciprofloxacin, danofloxacin, difloxacin, enrofloxacin, flumequine, marbofloxacine and oxolinic acid” with detection limit of 12.5–22.5 ppb
0.35 kg/m² respectively; \( p = 0.017 \) and in mothers with history of NSAID intake (−0.57 ± 0.47, −2.01 ± 0.46 kg/m² respectively; \( p = 0.038 \)) after adjusting confounding factors (Table 5). Similarly, compared to unexposed groups, maternal history of self-use of any antibiotics after delivery decreased maternal BMI improvement after delivery after adjusting control groups (Table 6).

Table 3 Maternal-infant characteristics according to the presence of anti-inflammatory drug residues in breast milk

| Maternal characteristics                                      | Anti-inflammatory drug residues | \( P \) |
|---------------------------------------------------------------|---------------------------------|--------|
| Maternal age, yrs                                             | 31.4 ± 4.4                      | 31.5 ± 4.0 | 0.940 |
| Maternal education> 12 yrs                                     | 63.0                            | 63.0 | 0.340 |
| Working in a revenue-generating business                       | 25.4                            | 37.0 | 0.264 |
| Anti-inflammatory drug use during breastfeeding period         | 57.1                            | 44.4 | 0.268 |
| Antibiotic drug use during breastfeeding period                | 41.3                            | 44.4 | 0.780 |
| Vitamin / mineral use during breastfeeding period              | 41.3                            | 48.1 | 0.546 |
| Any drug use during breastfeeding period                        | 84.1                            | 81.5 | 0.764 |
| Maternal cigarette contact, active or passive                 | 38.1                            | 48.1 | 0.374 |
| Edinburgh postpartum depression score ≥ 13                    | 14.3                            | 22.2 | 0.368 |
| Mother BMI (kg/m²) at delivery                                 | 27.9 ± 4.4                      | 27.5 ± 4.8 | 0.758 |
| Mother BMI (kg/m²) on admission                                | 25.8 ± 3.6                      | 27.1 ± 5.2 | 0.203 |

Infant characteristics

| Infant age, days                                               | 57.6 ± 17.8                     | 58.3 ± 19.1 | 0.867 |
| Infant age < 60 days                                           | 39.7                            | 33.3 | 0.569 |
| Male sex                                                       | 41.3                            | 44.4 | 0.780 |
| Delivery type, cesarean section                                | 71.4                            | 62.9 | 0.427 |
| Birth order> 1                                                 | 46.6                            | 48.1 | 0.854 |
| Gestation time < 38 weeks                                      | 27.0                            | 40.7 | 0.196 |
| Gestation time, weeks                                          | 38.2 ± 1.3                      | 38.1 ± 1.5 | 0.974 |
| Birthweight, WAZ                                               | −0.32 ± 0.85                    | −0.27 ± 1.41 | 0.857 |
| Intensive care requirement                                     | 17.5                            | 29.6 | 0.195 |
| Hyperbilirubinemia                                             | 31.7                            | 51.9 | 0.071 |
| Any underlying disease                                         | 22.2                            | 14.8 | 0.421 |
| Sleep disorder                                                 | 27.0                            | 37.0 | 0.340 |
| Excessive crying > 2 h                                          | 15.9                            | 11.1 | 0.556 |
| Inconsolable crying                                            | 9.5                             | 3.7 | 0.670 |
| Breastfeeding problem                                          | 28.6                            | 48.1 | 0.073 |
| Exclusive breastfeeding                                         | 77.8                            | 85.2 | 0.421 |
| WAZ score on admission                                         | −0.4 ± 1.2                      | 0.1 ± 1.4 | 0.106 |
| HCZ score on admission                                         | −0.2 ± 1.3                      | 0.1 ± 1.4 | 0.316 |

Values were mean ± SD or %

When confounding factors were controlled, WAZ scores of infants with antibiotic residues in their breast milk were similar to unexposed groups (Table 6).

Discussion

In our study, although it was not used by the mothers themselves, nearly all mother’s milk samples contained some residuals from medicines used in the area of livestock fattening. Only a minority of mothers milk (\( n = 4 \)) had no drug residues. This is the second article showing the residues of veterinary drugs in human milk [18].

Remnants of NSAID were found in the milk of 27 of 90 mothers included in our study in Ankara, all
containing tolfenamic acid. Tolfenamic acid is for the management of both acute and chronic pain in animals and indicated a long half-life in sheep [35]. Previous studies didn’t detect any remnants of tolfenamic acid in 83 studied human milk samples in Eskişehir [18]. However, one or two of samples contained chlormadione, metamizole, and meloxicam in both the Ankara and Eskişehir studies. Most of the drug residues in our study in Ankara were found to be quinolone and beta-lactam antibiotics in our study in Ankara. The Eskişehir study revealed 85.5% of breast milk with beta-lactam residues, however, a lower detection rate for quinolone residues (14.5%) [18]. Of the human’s milk in our study, 31.1% aminoglycoside residues and 3.3% polymixin residues were found and no residues in the assays of tetracycline, polypeptide and growth promoter drugs were detected in our study. The Eskişehir study revealed 4.8% polymixin, and only 2.4% aminoglycoside (tobramycin) [18]. This might be explained by different contamination of consumed foods in different cities. A minority of samples had amphenicol, sulphonamide, and corticosteroid residues in both cities.

To explicate veterinary drug residues in human milk, we must examine studies in animal products. Honey samples from 22 different regions of Turkey such as Muş, Bingöl, Şemdinli, Yüksekova and Marmaris-Muğla

**Table 4 Maternal-infant characteristics according to the presence of aminoglycoside drug residues in breast milk**

| Maternal characteristics | Aminoglycoside residues | | Polymixin residues | |
|--------------------------|-------------------------|------------------|-------------------|------------------|
|                          | Negative (n = 62)        | Positive (n = 28) | P                 | Negative (n = 78) | Positive (n = 12) | p |
| Age, yrs                 | 32.0 ± 4.4               | 30.5 ± 3.6       | 0.132             | 31.7 ± 4.3       | 30.2 ± 3.9       | 0.255 |
| Education > 12 yrs       | 69.3                    | 71.2             | 0.842             | 71.8             | 58.3             | 0.335 |
| Working mothers          | 30.6                    | 25.0             | 0.584             | 29.5             | 25.0             | 1.000 |
| NSAID use during postpartum period | 59.7 | 39.3 | 0.073 | 56.4 | 33.3 | 0.136 |
| Antibiotic drug use during postpartum period | 41.9 | 42.9 | 0.935 | 41.0 | 50.0 | 0.558 |
| Vitamin/mineral use during postpartum period | 40.3 | 50.0 | 0.391 | 41.0 | 58.3 | 0.260 |
| Any drug use during postpartum period | 82.3 | 85.7 | 0.769 | 83.3 | 83.3 | 1.000 |
| Maternal cigarette exposure, active or passive | 38.7 | 46.4 | 0.491 | 42.3 | 33.3 | 0.755 |
| EPDS on admission ≥13    | 14.5                    | 21.4             | 0.542             | 17.9             | 8.3             | 0.682 |
| EPDS on admission        | 6.87 ± 4.65             | 8.21 ± 6.42      | 0.265             | 7.60 ± 5.33      | 5.25 ± 4.49      | 0.151 |
| Maternal BMI at birth, kg/m² | 28.0 ± 4.8             | 27.2 ± 3.8       | 0.420             | 27.8 ± 4.6       | 27.7 ± 3.7       | 0.945 |
| Maternal BMI at visit, kg/m² | 26.2 ± 4.4             | 26.2 ± 3.7       | 0.993             | 26.3 ± 4.3       | 25.8 ± 3.5       | 0.739 |
| Infant characteristics   |                         |                  |                   |                  |                  |     |
| Age, day                 | 59.0 ± 18.1             | 55.1 ± 18.2      | 0.346             | 58.1 ± 18.4      | 56.0 ± 16.8      | 0.706 |
| Infant age < 60 days     | 33.9                    | 46.4             | 0.255             | 37.2             | 41.7             | 0.765 |
| Male sex                 | 40.3                    | 46.4             | 0.587             | 41.0             | 50.0             | 0.558 |
| Delivery, Cesarean section | 72.6                   | 60.7             | 0.260             | 67.9             | 75.0             | 0.747 |
| Birth order > 1          | 48.4                    | 42.9             | 0.626             | 48.7             | 33.3             | 0.320 |
| Gestation length < 38 weeks | 33.9                   | 25.0             | 0.400             | 32.1             | 25.0             | 0.747 |
| Gestational length, weeks | 38.0 ± 1.3            | 38.6 ± 1.5       | 0.050*            | 38.1 ± 1.4       | 38.6 ± 1.2       | 0.254 |
| Birthweight, WAZ         | –0.35 ± 1.06            | –0.19 ± 1.04     | 0.494             | –0.32 ± 1.02     | –0.23 ± 1.26     | 0.794 |
| Intensive care requirement | 17.7                   | 28.6             | 0.244             | 19.2             | 33.3             | 0.271 |
| Neonatal hyperbilirubinemia | 38.7                  | 35.7             | 0.786             | 38.5             | 33.3             | 1.000 |
| Any underlying disease   | 16.1                    | 28.6             | 0.170             | 35.9             | 25.0             | 0.534 |
| Sleep disorder           | 30.6                    | 28.6             | 0.842             | 29.5             | 33.3             | 0.747 |
| Excessive crying > 2 h   | 14.5                    | 14.3             | 0.977             | 15.4             | 8.3              | 1.000 |
| Inconsolable crying      | 9.7                     | 3.6              | 0.428             | 8.9              | 0.0              | 0.587 |
| Breastfeeding problem    | 32.3                    | 39.3             | 0.516             | 33.3             | 41.6             | 0.745 |
| Exclusive breastfeeding  | 77.4                    | 85.7             | 0.362             | 79.5             | 83.3             | 1.000 |
| WAZ score on admission   | –0.3 ± 1.3              | –0.2 ± 1.2       | 0.916             | –0.2 ± 1.3       | –0.3 ± 1.0       | 0.914 |
| HCZ score on admission   | 0.02 ± 1.3              | –0.3 ± 1.4       | 0.251             | 0.01 ± 1.4       | –0.7 ± 1.2       | 0.092 |

Values were mean ± SD or %
were investigated and although the use in beekeeping was not legal, tetracycline, streptomycin and sulfonamide group antibiotics were detected in 15% of the samples [36, 37]. One study analysed 240 pasteurized and raw milk samples sold in an Ankara market and detected oxytetracycline, penicillin G and neomycin in one milk sample above the maximum residual levels (MRL) allowed [38]. However, another study in Ankara in 2018 revealed 52.5% of milk samples had beta-lactam antibiotic residues above the detection limit (0.1 μg/kg) and 8.75% above 3 μg/kg [39]. However, in another study conducted in Ankara in 2010, 127 chicken meat and 104 beef samples from three different regions were selected randomly and quinolone group antibiotic residues were

| Breast milk residue | Maternal NSAID usage during postpartum period | Overall | P for residue | P for maternal self-use | Interaction between residue and self-use |
|---------------------|---------------------------------------------|---------|---------------|------------------------|----------------------------------------|
|                     | Absence                                      | Presence|               |                        |                                        |
| Maternal BMI change after birtha |
| NSAID –             | −2.77 ± 0.55                                 | −1.38 ± 0.46 | −2.07 ± 0.35 | 0.017 | 0.038 | 0.938 |
| NSAID +             | −1.26 ± 0.73                                 | 0.23 ± 0.81 | −0.51 ± 0.53 |                        |                                        |
| Overall             | −2.01 ± 0.46                                 | −0.57 ± 0.47 |               |                        |                                        |
| Infant’s WAZb       |
| NSAID –             | −0.13 ± 0.20                                 | −0.10 ± 0.16 | −0.11 ± 0.13 | 0.555 | 0.895 | 0.805 |
| NSAID +             | 0.07 ± 0.23                                  | −0.02 ± 0.32 | 0.03 ± 0.19 |                        |                                        |
| Overall             | −0.03 ± 0.15                                 | −0.06 ± 0.18 |               |                        |                                        |

Values were mean ± standard error of mean

* Analysed with general linear models adjusted for maternal age, smoke exposure, gestational length, birth type, maternal BMI at birth, maternal disease, breastfeeding type, infant age

| Breast milk residue | Maternal antibiotic usage during postpartum period | Overall | P for residue | P for maternal self-use | Interaction between residue and self-use |
|---------------------|-----------------------------------------------|---------|---------------|------------------------|----------------------------------------|
|                     | Absence                                      | Presence|               |                        |                                        |
| Maternal BMI change after birtha |
| Polymyxin –         | −2.53 ± 0.40                                 | −0.15 ± 0.48 | −1.34 ± 0.30 | 0.764 | 0.004 | 0.962 |
| Polymyxin +         | −2.81 ± 1.08                                 | −0.36 ± 1.09 | −1.59 ± 0.77 |                        |                                        |
| Overall             | −2.67 ± 0.57                                 | −0.26 ± 0.59 |               |                        |                                        |
| Infant’s WAZb       |
| Polymyxin –         | −0.20 ± 0.15                                 | 0.18 ± 0.17 | −0.01 ± 0.11 | 0.525 | 0.176 | 0.920 |
| Polymyxin +         | −0.42 ± 0.39                                 | 0.02 ± 0.39 | −0.20 ± 0.27 |                        |                                        |
| Overall             | −0.31 ± 0.21                                 | 0.10 ± 0.21 |               |                        |                                        |
| Maternal BMI change (kg/m²) after birtha |
| Aminoglycoside –    | −2.72 ± 0.45                                 | −0.39 ± 0.53 | −1.55 ± 0.34 | 0.364 | < 0.001 | 0.889 |
| Aminoglycoside +    | −2.23 ± 0.67                                 | 0.27 ± 0.79 | −0.98 ± 0.52 |                        |                                        |
| Overall             | −2.47 ± 0.40                                 | −0.06 ± 0.47 |               |                        |                                        |
| Infant’s WAZb       |
| Aminoglycoside –    | −0.17 ± 0.16                                 | 0.17 ± 0.20 | 0.00 ± 0.13 | 0.585 | 0.067 | 0.751 |
| Aminoglycoside +    | −0.36 ± 0.25                                 | 0.12 ± 0.25 | −0.12 ± 0.18 |                        |                                        |
| Overall             | −0.26 ± 0.15                                 | 0.15 ± 0.16 |               |                        |                                        |

Values were mean ± standard error of mean

* Analysed with general linear models adjusted for maternal age, smoke exposure, gestational length, birth type, maternal BMI at birth, maternal disease, breastfeeding type, infant age

* Exclusive breast fed infants were enrolled and analysed with general linear models adjusted for maternal age, maternal disease, smoke exposure, gestational length, birth type, infant’s WAZ at birth, infant age
detected in 45.7% of chicken meat samples and 57.7% of beef meat samples [7]. This may explain the detection of quinolone and beta-lactam in human milk in our study. Residues of veterinary medicinal products are a global problem [40]. In some African countries veterinary drug residues can be as high as 94% in foods of animal origin. In 10 provinces of China, 0.5, 47.2 and 20.1% of 199 raw milk samples were reported to be positive for beta-lactams, quinolones and sulfonamides, respectively at the detectable level [41]. A study from Nepal detected 81% samples positive for amoxicillin, 41% for sulfadimethoxine, 27% for penicillin G, and 12% for ampicillin in 140 fresh milk [6]. These reports can be explained by unnecessary use of antibiotics, ignorance of the prescribed drug use and the recommended pre-slaughter time by the people who practice fattening during the last decade [7, 42].

In our study, no significant relationship was found between the presence of drug residues in mothers’ milk and PPD. In addition, antibiotic and NSAID residues found in breast milk did not have any influence on crying and sleep problems. However, in cases with NSAID residues, neonatal jaundice and breastfeeding problems were detected slightly higher (p = 0.071 and p = 0.073) which was not found to be statistically significant. NSAIDs are consumed widely during the early lactational period [17]. On the other hand, it is known that NSAIDs have a risk for renal injury, constriction of the ductus arteriosus, necrotizing enterocolitis and intracranial haemorrhage when used in the third trimester of gestation [11]. Therefore, further detailed studies in lactating mothers with pharmaceutical intake are necessary to clarify this hypothesis.

It is observed that the presence of NSAID residues has an impact on postnatal maternal weight regulation and may slow down the return of the mother to prepregnancy weight. In addition, in the present study, maternal self-use of antibiotics was shown to have a similar effect on maternal postpartum weight change. There has been no study evaluating the influence of analgesic drug usage on the mother’s BMI. However, recent studies showed the association of antibiotic use with obesity in childhood period [43, 44]. Rogawski et al. reported that antibiotic use in the first 6 months of life was associated with increased weight, especially among children with two or more exposures to macrolides, metronidazole, and cephalosporins [43]. Similarly, Block et al. found that antibiotic use at < 24 months of age was associated with a slightly higher body weight at 5 years of age [44]. The changes in anthropometric parameters are explained by the influence of antibiotics on the diversity and composition of the gut microbiota, which can persist long after the treatment and can modify metabolism and energy harvest of the diet [45–47]. Similarly, antibiotics including tetracyclines, macrolides, avoparcin and penicillins have been commonly used in livestock to promote growth and increase weight gain [48]. We detected no influence of antibiotic residues on infant’s anthropometric evaluations. This might be due to the small amount of residues in breast milk. However, a cause-effect relationship could not be established between drug residues and the health parameters of the mother and child with a single assessment in our study. Because of infant and maternal health concern, more extensive studies are needed to illuminate this outcome. Nonetheless, this predicted impact should be particularly emphasised and unnecessary drug use should be prevented.

**Strengths and limitations**

Our study is the first comprehensive one examining the presence of veterinary drug residues in human milk and the relationship between the baby and maternal problems. We enrolled nursing mothers with babies younger than 3 months and receiving no complementary food. This way, the infants who might be exposed to different pollutants through food were not factored into the study. Our study also showed drug residues similar to contaminant in animal husbandry in the experimental region. Given that one milk sample from nursing mothers shows the current environmental status of mother-infant pairs, however, as a limitation we could not determine the past contamination.

Significant time-dependent changes in water, lipid and protein content of human milk are well known. Therefore, carry-over content though milk might be change in foremilk and hindmilk [49]. We planned to see content of foremilk in the natural situation. Nursing a baby stimulates the maternal oxytocin response and provides milking by a physiological mechanism. Considering this fact, we took breastmilk at the fifth minute of sucking by a hand milking method. So, we examined only the presence of contaminants in foremilk. These same techniques and methodologic procedures could be used in further studies. This will enable method standardisation.

In our study, the amount of drug residues was not determined and this was a limitation of the study. Previous studies had evaluated assay methods to determine drugs residues in animal products following self-consumption [50]. However, there is no kit specific to human milk. Therefore, we used InfiniPlex Biochip kit intended to test milk meant to be consumed as food [34]. Detection of very low doses of residuals with traceable technology is the strength of our study (Additional file 1: Table S1). Multiresidue methods can make visible the problems in different areas [51]. Our descriptive study is performed for the evaluation of problems and screened for multiple drug residues. Our study points to the possibility for
further studies on this subject. Further quantitative studies can be planned on these detected residues.

**Conclusions**
The majority of the mothers included in the study had drug residues in their breast milk. These results show that mothers are exposed to drugs in an unexpected manner through foods and what’s more, some of these drugs detected in breast milk are prohibited in humans. In our study, the impact of residues in the mother’s milk on baby sleep and crying problems, breastfeeding problems and PPD were not found to be significant. However, drug residues were found to influence the regulation of the anthropometric parameters of the mother.

Preventing unnecessary drug exposure in mother-baby pairs is extremely important for healthy generations. Therefore, veterinary medicinal products must be used in appropriate indications; obedience to appropriate waiting time must be monitored.

**Supplementary information**
Supplementary information accompanies this paper at https://doi.org/10.1186/s12884-019-2506-1.

**Additional file 1: Table S1.** Detection limits of residues for Randox biochip array technology.

**Abbreviations**
AB: Antibiotic; BMI: Body mass index; EPDS: Edinburgh Postpartum Depression Scale; EU: European Union; HAZ: Z scores of length; HCZ: Z scores of head circumference; NSAID: Nonsteroid antinflammatory drugs; PP: Postpartum; PPD: Postpartum depression; SD: Standard deviation; SPSS: Statistical Package for the Social Sciences; WAZ: Z scores of weight

**Acknowledgements**
The authors are grateful to Samet ECE from Diagen Biyoteknolojik Sistemler A.Ş. for RANDOX tests application. Our manuscript was edited by a professional editing service; Scribendi order number:618298.

**Authors’ contributions**
SSY conceptualized and designed the study, analyzed the data, reviewed and revised the manuscript. AME contributed to the conceptualization and design of the study, collected the data, drafted the initial manuscript, revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**Funding**
Financial support for test kits and materials of milk multidrug residues were made possible by Hacettepe University Scientific Research Projects Coordination Unit (project no. THD-2017-15742). But this organization was not involved in designing the concept of this study, analysis, interpretation of data and in preparation of the manuscript draft. This organization also did not cover any fund for publication.

**Availability of data and materials**
The datasets used during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
Hacettepe University Medical Faculty Non-Interventional Clinical Research Ethics Committee was approved with the report numbered GO 17/687 on August 24, 2017. Mothers who participated in the study signed voluntary consent form.

**Consent for publication**
There is no individual person's data.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Department of Family Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. 2Unit of Social Pediatrics, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

**Received:** 5 December 2018 **Accepted:** 12 September 2019
**Published online:** 11 October 2019

**References**
1. Orelli D, Sporri AS, Edder P. Veterinary drug residue in food of animal origin in Switzerland: a health concern? Chimia. 2018;72(10):713–7.
2. Pereira A, Silva LIG, Rodrigues J, Lino C, Peres A. Risk assessment of fluoroquinolones from poultry muscle consumption: comparing healthy adult and pre-school populations. Food Chem Toxicol. 2018;118:340–7.
3. Olayoye IO, Daniel OF, Ishola SA. Screening of antibiotics and chemical analysis of penicillin residue in fresh milk and traditional dairy products in Oyo state, Nigeria. Veterinary world. 2016;9(9):948–54.
4. Moghadam MM, Amir M, Rabi HR, Ribi HR. Evaluation of Antibiotic Residues in Pasteurized and Raw Milk Distributed in the South of Khorasan-e Razavi Province. Iran. J Clin Diag Res. JCDR. 2016;10(12):F31–F35.
5. Redding LE, Cubas-Delgado F, Sammel MD, Smith G, Galligan DT, Levy MZ, Hennessy S. Antibiotic residues in milk from small dairy farms in rural Peru. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;31(6):1001–8.
6. Khanal BKS, Sadig MB, Singh M, Anal AK. Screening of antibiotic residues in fresh milk of Kathmandu Valley, Nepal. J Environ Sci Health B. 2018;53(1):57–86.
7. Er B, Onurdag FK, Demirhan B, Ozgacar SO, Oktem AB, Abbasoglu U. Screening of quinolone antibiotic residues in chicken meat and beef sold in the markets of Ankara, Turkey. Poult Sci. 2013;92(8):2212–5.
8. Yamaguchi T, Okihashi M, Harada K, Konishi Y, Uchida K, Do MH, Bui HD, Nguyen TD, Nguyen PD, Chau VV, et al. Antibiotic residue monitoring results for pork, chicken, and beef samples in Vietnam in 2012-2013. J Agric Food Chem. 2015;63(21):5141–5.
9. Lee HC, Chen CM, Wei JT, Chiu HY. Analysis of veterinary drug residue monitoring results for commercial livestock products in Taiwan between 2011 and 2015. J Food Drug Anal. 2018;26(2):565–71.
10. Anderson PO, Manoguerra AS, Valdes V. A review of adverse reactions in infants from medications in breastmilk. Clin Pediatr. 2016;55(3):236–44.
11. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063–75.
12. Hirsch AG, Pollak J, Glass TA, Poulsen MN, Bailey-Davis L, Mowery J, Schwartz BS. Early-life antibiotic use and subsequent diagnosis of food allergy and allergic diseases. Clin Exp Allergy. 2017;47(2):236–44.
13. Baynes RE, Dedonder K, Kissell L, Myky D, Marmulak T, Smith G, Tell L, Gehring R, Davis J, Riviere JE. Health concerns and management of select veterinary drug residues. Food Chem Toxicol. 2016;88:112–22.
14. Sachs HC. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(6):e966–809.
15. Anadón A, Martínez-Larrañaga MR, Ramos E, Castellano V. Transfer of drugs and xenobiotics through milk. In: Gupta RC. (ed). Reproductive and developmental toxicology. London, Elsevier; 2011. p. 57–71.
16. Seedat F, Stinton C, Patterson J, Geppert J, Tan B, Robinson ER, McCarthy ND, Uthman OA, Freeman K, Johnson SA, et al. Adverse events in women and children who have received intrapartum antibiotic prophylaxis treatment: a systematic review. BMC pregnancy and childbirth. 2011;11(1):247.
17. Anderson PO. Drugs in lactation. Pharm Res. 2018;35(3):845.
18. Dinleyici M, Yildirim GK, Aydemir O, Kaya TB, Bildirici Y, Carman KB. Human milk antibiotic residue levels and their relationship with delivery mode, maternal antibiotic use and maternal dietary habits. Eur Rev Med Pharmacol Sci. 2018;22(1):6580–6.
